Ocera Therapeutics fka OCRX

[ghmm]

Looking over the 10Q here are things I noticed:


1) Enrollment Figures From Q/K
As Of 9/30/15 110
as of 2/29/16 150
as of 4/29/16 165

So really no big step up in enrollment (7-8 avg) maybe a bit worse when figuring december/january likely slow and summer in EU things slow down so if pick up need it to be in Q2 otherwise maybe into Q1 to hit 230+.

2) Here is more info on the NIH study

In addition, there is an investigator-sponsored Phase 2a clinical trial being conducted by the National Institutes of Health, or NIH, to evaluate the safety of OCR-002 in patients with hyperammonemia and HE due to acute liver failure or injury. In November 2015, the NIH announced preliminary pK data on 22 patients and concluded that OCR-002 was safe and well-tolerated at the levels administered, up to 10 grams per 24 hours. A correlation was observed between the doses administered and the drug levels seen in the blood, but even at the 10 gram dose, the investigators deemed the exposure of the drug to be below the desired range. As a result, they are now enrolling an additional 12 patients at a higher dose of 20 grams per 24 hours and expect to complete enrollment in the fourth quarter of 2016. Data is expected to be available from this trial in the first half of 2017.

3) Also In Q1 sold 600k shares under ATM at avg price of $3.